Since MUC5AC induces chemical resistance through CR44/β-catenin/p53/p21 signaling in CRC 107, combination therapy with gene editing tools and chemotherapeutic agents can break CRC resistance to conventional chemotherapies [121]. Here, MUC5AC is linked to colorectal carcinoma.